Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

20.57 -0.04 (-0.19%)
Streaming Delayed Price Updated: 3:27 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss market. See how their financials and risk profiles compare. 
Via The Motley Fool
News headline image
Dyne Therapeutics Appoints Barry Greene to Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗
Via Chartmill
News headline image
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗
The company is attracting much investor attention this week because of what happened in the lab. 
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.